A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

BMC Health Services Research

Volumn 9, Issue , 2009, Pages

  Treur, Maarten ^a   Heeg, Bart ^a   Möller, Hans Jürgen ^b   Schmeding, Annette ^c   Van Hout, Ben ^a  

^a PHARMERIT INTERNATIONAL   (Netherlands)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c JANSSEN CILAG GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; GENERIC DRUG; NEUROLEPTIC AGENT;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SUBSTITUTION; GERMANY; HOSPITALIZATION; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PROBABILITY; SCHIZOPHRENIA; ECONOMICS; PHARMACOECONOMICS; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; THEORETICAL MODEL;

ANTIPSYCHOTIC AGENTS; DRUGS, GENERIC; ECONOMICS, PHARMACEUTICAL; GERMANY; HUMANS; MODELS, THEORETICAL; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; RISPERIDONE; SCHIZOPHRENIA;

EID: 61849171899     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-9-32     Document Type: Article

References (35)

1. Adherence to treatment with antipsychotic medication and health care costs among medicaid beneficiaries with schizophrenia. TP Gilmer CR Dolder JP Lacro DP Folsom L Lindamer P Garcia, Am J Psychiatry 2004 161 692 699 10.1176/appi.ajp.161.4.692 15056516
2. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. M Valenstein D Ganoczy JF McCarthy KH Myra TA Lee FC Blow, J Clin Psychiatry 2006 67 1542 1550 17107245
3. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. JP Lacro LB Dunn CR Dolder SG Leckband DV Jeste, J Clin Psychiatry 2002 63 892 909 12416599
4. Determinants of medication compliance in schizophrenia: empirical and clinical findings. WS Fenton CR Blyler RK Heinssen, Schizophr Bull 1997 23 637 651 9366000
5. Medication noncompliance in schizophrenia: codification and update. JL Young HV Zonana L Shepler, Bull Am Acad Psychiatry Law 1986 14 105 122 2873851
6. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. M Eaddy A Grogg J Locklear, Clin Ther 2005 27 263 272 10.1016/j.clinthera.2005.02.003 15811492
7. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. P Weiden C Kozma A Grogg J Locklear, Psychiatric Services 2004 55 886 891 10.1176/appi.ps.55.8.886 15292538
8. Factors influencing compliance in schizophrenia patients. W Fleischhacker M Oehl M Hummer, J Clin Psychiatry 2003 64 Suppl 16 S10 S13 14680413
9. Bioequivalence and other unresolved issues in generic drug substitution. P Meredith, Clin Ther 2003 25 2875 2890 10.1016/S0149-2918(03)80340-5 14693311
10. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. G Borgheini, Clin Ther 2003 25 1578 1592 10.1016/S0149-2918(03)80157-1 12860486
11. Consumer perceptions of risk and required cost savings for generic prescription drugs. JM Ganther DH Kreling, J Am Pharm Assoc (Wash) 2000 40 378 383 10853539
12. The generic alternative in schizophrenia: opportunity or threat? P Nuss D Taylor M De Hert M Hummer, CNS Drugs 2004 18 769 775 10.2165/00023210- 200418120-00002 15377167
13. The global costs of schizophrenia. M Knapp R Mangalore J Simon, Schizophr Bull 2004 30 279 93 15279046
14. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. G Laux BMS Heeg BA van Hout A Mehnert, Pharmacoeconomics 2005 23 49 61 10.2165/00019053-200523001-00005 16416761
15. Modelling the treated course of schizophrenia: development of a discrete event simulation model. BMS Heeg E Buskens M Knapp G van Aalst P Dries L de Haan, Pharmacoeconomics 2005 23 17 33 10.2165/00019053-200523001-00003 16416759
16. Selecting a decision model for economic evaluation: a case study and review. J Karnon J Brown, Health care manag sci 1998 1 133 140 10.1023/A:1019090401655 10916592
17. Modelling approaches for schizophrenia. BMS Heeg J Damen E Buskens SdCF Caleo BA van Hout, Pharmacoeconomics 2008 26 633 648 10.2165/00019053-200826080- 00002 18620458
18. The cost-effectiveness of atypicals in the UK. B Heeg E Buskens M Botteman S Caleo M Ingham J Damen, Value in Health 2008 18489517
19. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. L Lenert A Sturley M Rapaport M Rupnow S Chavez PE Mohr, Schizophr Res 2004 71 155 165 10.1016/j.schres.2003.10.010 15374583
20. An economic review of compliance therapy with medication in the treatment of schizophrenia. P Thieda S Beard A Richter J Kane, Psychiatric Services 2003 54 508 516 10.1176/appi.ps.54.4.508 12663838
21. Prediciting medication non-compliance after hospitalization discharge among patients with schizophrenia. M Olfson D Mechanic S Hansell, Psychiatry Services 2000 51 216 222 10.1176/appi.ps.51.2.216
22. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. J Geddes N Freemantle P Harrison P Bebbington, BMJ 2000 321 1371 1376 11099280 10.1136/bmj.321.7273.1371
23. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. JP Lindenmayer P Czobor J Volavka JA Lieberman L Citrome B Sheitman, J Clin Psychiatry 2004 65 551 556 15119920
24. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. G Rubio I Martinez G Ponce MA Jimenez-Arriero F Lopez-Munoz C Alamo, Can J Psychiatry 2006 51 531 539 16933590
25. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder; symptoms, quality of life and resource use under customary clinical care. R Mahmoud L Engelhart C Janagap G Oster D Ollendorf, Clin Drug Investig 2004 24 5 275 286 10.2165/00044011-200424050-00004 17503889
26. Health Care Insurance Board, Pharmacopoeia the Netherlands Amstelveen: Health Care Insurance Board 2002
27. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. GE Hunt J Bergen M Bashir, schizophrenia research 2002 54 253 264 10.1016/S0920-9964(01)00261-4 11950550
28. Depot neuroleptics: the relevance of psychosocial factors - a United States perspective. GE Hogarty, J Clin Psychiatry 1984 45 36 42 6143746
29. Lauer - Taxe Online Pharmaceutical Database. GmbH Lauer Fischer, 2007
30. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. JC Kluznik NH Walbek MG Farnsworth K Melstrom, J Clin Psychiatry 2001 62 Suppl 5 14 17 11305843
31. Phenothiazine intake and staff attitudes. DS Irwin WD Weitzel DW Morgan, Am J Psychiatry 1971 127 1631 1635 5565846
32. Drug default among schizophrenic patients. AA Nelson Jr BH Gold RA Hutchinson E Benezra, Am J Hosp Pharm 1975 32 1237 1242 1108645
33. Untersuchungen zu den direkten Kosten und indirekten kosten der schizophrenie. JMG von der Schulenburg A Uber J Höffler, Gesundh kon Qual Manag 1998 3 81 87
34. OECD. Stat Extracts. Organization for Economic Co-Operation and Development, 2008
35. The course of schizophrenia over 13 years; A report from the international study on schizophrenia (ISos) coordinated by the World Health Organisation. P Mason G Harrison C Glazebrook I Medley T Croudace, British Journal of Psychiatry 1996 169 580 586 10.1192/bjp.169.5.580 8932886